In this review:
- Golcadomide + R-CHOP in high-grade B-cell lymphomas
- Atezolizumab consolidation in DLBCL (HOVON 151)
- Biomarker-adapted treatment in high-risk DLBCL
- Real-world CAR T-cell therapy for relapsed/ refractory DLBCL patients aged >75 years
- BrECADD vs. BEACOPP in advanced-stage classical Hodgkin lymphoma (HD21)
- Gonadal function recovery and fertility in HD21 trial
- Isatuximab-VRd vs. VRd in transplant-ineligible newly diagnosed myeloma
- Asciminib vs. TKIs in newly diagnosed CML
- Glofitamab-gemcitabine oxaliplatin for relapsed/ refractory DLBCL (STARGLO)
- 7-year phase 2 trial update of obinutuzumab-ibrutinib venetoclax for CLL
Please login below to download this issue (PDF)